Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0K2PH
|
|||
| Former ID |
DNC000601
|
|||
| Drug Name |
Elvucitabine
|
|||
| Synonyms |
Elvucitabine; beta-L-Fd4C; 181785-84-2; UNII-M09BUF90C0; L-F-D4C; L-D4FC; ACH-126443; ACH-126,443; M09BUF90C0; 4-amino-5-fluoro-1-[(2S,5R)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]pyrimidin-2-one; ACH 126443; 4-amino-5-fluoro-1-[(2s,5r)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]pyrimidin-2(1h)-one; L-Fd4C; Elvucitabine [USAN:INN]; 4-amino-5-fluoro-1-((2S,5R)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl)pyrimidin-2(1H)-one; ACH 126,443; AC1LAJSF; AC1Q4HKY; Elvucitabine (USAN/INN); CHEMBL38700; ZINC7048; SCHEMBL1649928; CTK4D7977
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Human immunodeficiency virus infection [ICD-11: 1C62; ICD-9: 279.3] | Discontinued in Phase 2 | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C9H10FN3O3
|
|||
| Canonical SMILES |
C1=CC(OC1CO)N2C=C(C(=NC2=O)N)F
|
|||
| InChI |
1S/C9H10FN3O3/c10-6-3-13(9(15)12-8(6)11)7-2-1-5(4-14)16-7/h1-3,5,7,14H,4H2,(H2,11,12,15)/t5-,7+/m1/s1
|
|||
| InChIKey |
HSBKFSPNDWWPSL-VDTYLAMSSA-N
|
|||
| CAS Number |
CAS 181785-84-2
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Human immunodeficiency virus Reverse transcriptase (HIV RT) | Target Info | Modulator | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007421) | |||
| REF 2 | Multiple-dose pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered over 21 days with lopinavir-ritonavir in human immunodeficiency virus type 1-infected subjects.Antimicrob Agents Chemother.2009 Feb;53(2):662-9. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.